MedTrace Logo

Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes

NCT01917656 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 343

Last updated 2017-08-24

Study results available
· View outcomes & findings →

Summary

This trial is conducted in Africa and Asia. The aim of the trial is to investigate the efficacy and safety of liraglutide versus sulphonylurea (SU) both in combination with metformin during Ramadan in subjects with type 2 diabetes (T2DM).

Conditions

Interventions

DRUG

liraglutide

1.8 mg administered subcutaneously (s.c., under the skin) once daily

DRUG

metformin

Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged

DRUG

sulphonylurea

Subjects will continue on their pre-trial SU tablet treatment, doses unchanged

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-09
Primary Completion
2014-09-01
Completion
2014-09-04

Countries

  • Algeria
  • India
  • Israel
  • Lebanon
  • Malaysia
  • South Africa
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01917656 on ClinicalTrials.gov